Skip to content

Immunovant, Inc. IMVT Cash Flow Statement

Q4 '26Q3 '26Q2 '26Q1 '26Q4 '25
-$147.86M-38.9%-$110.64M+0.4%-$126.5M-15.9%-$120.61M-38.4%-$106.45M-41.3%
$96K-11.9%$101K+2.0%$105K+18.0%$107K+33.8%$109K+70.3%
$11.14M-4.7%$12.72M+9.1%$13.36M+5.2%$18.51M+37.6%$11.69M+20.7%
-$95.06M+14.1%-$92.33M+8.0%-$102.52M-15.6%-$117.41M-54.1%-$110.64M-85.3%
$8K-96.0%$0-100%$0-100%$0-100%$201K+34.0%
-$8K+96.0%$0+100%$0+100%$0+100%-$201K-34.0%
$3.64M-99.2%$564.6M+22,814%$24.6M+3,269%$2.92M+325%$450.61M+29,066%
$472.66M+581%-$77.04M+11.5%-$115.06M-52.7%$339.29M
-$95.07M+14.2%-$92.33M+8.2%-$102.52M-15.4%-$117.41M-53.7%-$110.84M-85.2%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Immunovant, Inc. generate?
Immunovant, Inc. (IMVT) generated -$407.3M in operating cash flow over the trailing twelve months.
What is Immunovant, Inc.'s free cash flow?
After $8.0K of capital expenditures, Immunovant, Inc.'s free cash flow was -$407.3M over the trailing twelve months, down 8.2% year over year.
Where does Immunovant, Inc.'s cash flow data come from?
Every line is extracted from Immunovant, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.